Intravenous rt-PA: a tenth anniversary reflection

Surgical Neurology

Volumn 68, Issue 5 SUPPL., 2007, Pages

  Grotta, James ^a   Marler, John ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

rt PA; Stroke; Treatment

Indexed keywords

ALTEPLASE;

ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; FOLLOW UP; GLASGOW COMA SCALE; HEALTH PROGRAM; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; STROKE; TREATMENT OUTCOME; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; INTRACRANIAL THROMBOSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 35348998944     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surneu.2007.07.079     Document Type: Article

References (54)

1. Adams H.P., Brott T.G., Furlan A.J., Gomez C.R., Grotta J., Helgason C.M., Kwiatkowski T., Lyden P.D., Marler J.R., Torner J., Feinberg W., Mayberg M., and Thies W. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 94 (1996) 1167-1174
2. Adams Jr. H.P., Kenton III E.J., Scheiber S.C., and Juul D. Vascular neurology: a new neurologic subspecialty. Neurology 63 5 (2004) 774-776
3. Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., and Hamilton S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150
4. Alberts M.J., Hademenos G., Latchaw R.E., Jagoda A., Marler J.R., Mayberg M.R., Starke R.D., Todd H.W., Viste K.M., Girgus M., Shephard T., Emr M., Shwayder P., and Walker M.D. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 283 23 (2000) 3102-3109
5. Alexandrov A.V., Molina C.A., Grotta J.C., Garami Z., Ford S.R., Alvarez-Sabine J., Montaner J., Saqqur M., Demchuk A.M., Moye L.A., Hill M.D., Wojner A.W., and CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 (2004) 2170-2178
6. Alexandrov A.V., and Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59 (2002) 862-867
7. The Brain Attack Coalition internet web site http://www.stroke-site.org. Members of the Leadership Committee are the American Academy of Neurology, American Association of Neurological Surgeons, American Association of Neuroscience Nurses, American College of Emergency Physicians, American Society of Interventional and Therapeutic Neuroradiology, American Society of Neuroradiology, American Stroke Association, a Division of American Heart Association, Centers for Disease Control and Prevention Congress of Neurological Surgeons, National Association of EMS Physicians, National Association of State EMS Officials, National Institute of Neurological Disorders and Stroke, National Stroke Association, Stroke Belt Consortium, and Veterans Administration.
8. Broderick J.P., Lu M., Kothari R., Levine S.R., Lyden P.D., Haley E.C., Brott T.G., Grotta J.C., Tilley B.C., Marler J.R., and Frankel M. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA Stroke Trial. Stroke 31 (2000) 2335-2341
9. Brott T., Lu M., Kothari R., Fagan S., Frankel M., Grotta J., Broderick J., Kwiatkowski T., Lewandowski C., Haley C., Marler J., and Tilley B. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 29 (1998) 1504-1509
10. Brott T.G., Haley E.C., Levy D.E., Barsan W., Broderick J., Sheppard G.L., Spilker J., Kongable G.L., Massey S., and Reed R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23 5 (1992) 632-640
11. Caplan L., Mohr J., Kistler J., and Koroshetz W. Thrombolysis-not a panacea for ischemic stroke. N Engl J Med 337 18 (1997) 1309-1313
12. Clinicaltrials.gov NCT00046293. ReoPro and Retavase to treat acute stroke.
13. Clinicaltrials.gov NCT00153036. A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4.30 hours after stroke onset.
14. Clinicaltrials.gov NCT00238537. Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET).
15. Clinicaltrials.gov NCT00250991. Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial.
16. Clinicaltrials.gov NCT00389467. MR and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE).
17. Fagan S.C., Morgenstern L.B., Petitta A., Ward R.E., Tilley B.C., Marler J.R., Levine S.R., Broderick J.P., Kwiatkowski T.G., Frankel M., Brott T.G., and Walker M.D. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 50 4 (1998) 883-890
18. Fieschi C., Argentino C., Lenzi G.L., Sacchetti M.L., Toni D., and Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 91 3 (1989) 311-321
19. Grotta J., and Alexandrov A. tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke 29 (1998) 429-432
20. Grotta J.C., Burgin W.S., El-Mitwalli A., Long M., Campbell M., Morgenstern L.B., Malkoff M., and Alexandrov A. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996-2000. Arch Neurol 58 (2001) 2009-2013
21. Grotta J. t-PA-the best current option for most patients. N Engl J Med 337 18 (1998) 1310-1312
22. Grotta J.C., Welch K.M.A., Fagan S.C., Lu M., Frankel M.R., Brott T., Levine S.R., Lyden P.D., and and the NINDS rt-PA Stroke Study Group. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 32 (2001) 661-668
23. Hacke W., Albers G., Al-Rawl Y., Bogousslavsky J., Davalos A., Eliasziw M., Fisher M., Furlan A., Kaste M., Lees K.R., Soehngen M., Warach S., and DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 1 (2005) 66-73
24. Hacke W., Donnan G., Fieschi C., Kaste M., von Kummer R., Borderick J.P., Brott T., Frankel M., Grotta J.C., Haley Jr. E.C., Kwiatkowski T., Levine S.R., Lewandowski C., Lu M., Lyden P., Marler J.R., Patel S., Tilley B.C., Albers G., ATLANTIS Trials Investigators, ECASS Trials Investigators, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
25. Haley E., Lewandowski C., Tilley B., and NINDS rt-PA Stroke Study Group. Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med 30 (1997) 676-682
26. Haley Jr. E.C., Brott T.G., Sheppard G.L., Barsan W., Broderick J., Marler J.R., Kongable G.L., Spilker J., Massey S., Hansen C.A., et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 24 7 (1993) 1000-1004
27. Haley E.C., Levy D.E., Brott T.G., Sheppard G.L., Wong M.C., Kongable G.L., Torner J.C., and Marler J.R. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23 5 (1992) 641-645
28. Hoffman J., and Cooper R. Stroke thrombolysis: we need new data, not more reviews. Lancet Neurol 4 4 (2005) 204-205
29. The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke 35 (2004) 904-912
30. Ingal J.T., O'Fallon W.M., Asplund K., Goldfrank L.R., Hertzberg V.S., Louis T.A., and Christianson T.J. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 35 10 (2004) 2418-2424
31. International Stroke Trial-2.
32. Johnston S.C., Rootenberg J.D., Katrak S., Smith W.S., and Elkins J.S. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 367 9519 (2006) 1319-1327
33. Jones T.H., Morawetz R.B., Crowell R.M., Marcoux F.W., FitzGibbon S.J., DeGirolami U., and Ojemann R.G. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 54 6 (1981) 773-782
34. Katzan I.L., Furian A.J., Lloyd L.E., et al. Use of tissue-type plasminogen activator for treatment of acute stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
35. Kwiatkowski T., Libman R., Lewandowski C., Tilley B.C., Grotta J., Lyden P., Levine S., Brott T., and and the NINDS rt-PA Stroke Study Group. The impact of imbalances in baseline stroke severity on outcome in the NINDS rt-PA Stroke Study. Ann Emerg Med 45 (2005) 377-384
36. Kwiatkowski T.G., Libman R.B., Frankel M., Tilley B.C., Morgenstern L.B., Lu M., Broderick J.P., Lewandowski C.A., Marler J.R., Levine S.R., and Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 340 23 (1999) 1781-1787
37. Lewandowski C., Frankel M., Tomsick T., Broderick J., Frey J., Clark W., Starkman S., Grotta J., Spilker J., Khoury J., Brott T., and and the EMS Bridging Trial Investigators. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30 (1999) 2598-2605
38. Marchal G., Beaudouin V., Rioux P., et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke 27 (1996) 599-606
39. Marler J.R., Jones P.W., and Emr M. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. The National Institute of Neurological Disorders and Stroke. Bethesda, Maryland. August (1997)
40. Marler J.R., Tilley B.C., Lu M., Brott T.G., Lyden P.C., Grotta J.C., Broderick J.P., Levine S.R., Frankel M.P., Horowitz S.H., Haley Jr. E.C., Lewandowski C.A., Kwiatkowski T.P., and for the NINDS rt-PA Stroke Study Group. Early stroke treatment associated with better outcome. Neurology 55 (2000) 1649-1655
41. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
42. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke-subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28 (1997) 2119-2125
43. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28 (1997) 2109-2118
44. The NINDS t-PA Stroke Study Investigators. A systems approach to immediate evaluation and management of hyperacute stroke. Stroke 28 (1997) 1530-1540
45. Patel S.C., Levine S.R., Tilley B.C., Grotta J.C., Lu M., Frankel M., Haley E.C., Brott T.G., Broderick J.P., Horowitz S., Lyden P.D., Lewandowski C.A., Marler J.R., Welch M.K.A., and for the NINDS rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 286 (2001) 2830-2838
46. Schmuilling S., Grond M., Rudolf J., and Heiss W.D. One year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 31 (2000) 1552-1554
47. Smith W.S., and for the Multi MERCI Investigators. Safety of mechanical thombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I. AJNR Am J Neuroradiol 27 (2006) 1177-1182
48. Smith W.S., Sung G., Starkman S., et al., and the MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36 (2005) 1432-1438
49. Sugg R.M., Pary J.K., Uchino K., Baraniuk S., Shaltoni H.M., Gonzales N.R., Mikulik R., Garami Z., Shaw S.G., Matherne D.E., Moyé L.A., Alexandrov A.V., and Grotta J.C. Argatroban tPA Stroke Study: design and results in the first treated cohort. Arch Neurol 63 (2006) 1057-1062
50. Tanne D., Bates V.E., Verro P., and and the t-PA Stroke Survey Group. Initial clinical experience with IV tissue plasminogen activator for the acute ischemic stroke: a multicenter survey. Neurology 53 (1999) 424-427
51. Tilley B., Lyden P., Brott T., Lu M., Levine S., Welch K., and for the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. Archives of Neurology 54 (1997) 1466-1474
52. Wahlgren N., Ahmed N., Davalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 9558 (2007) 275-282
53. Wojner-Alexandrov A.W., Alexandrov A.V., Rodrigues D., Persse D., and Grotta J.C. Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO). Stroke 36 (2005) 1512-1518
54. Zivin J.A., Fisher M., DeGirolami U., Hemenway C.C., and Stashak J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230 4731 (1985) 1289-1292